Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Acetylcholinesterase (AChE) is a primary target for Alzheimer's therapy while recently sodium glucose cotransporter 2 (SGLT2) has gained importance as a potential target for Type 2 Diabetes Mellitus (T2DM) therapy. The present study emphasizes the molecular interactions between a new Food and Drug Administration (FDA) approved antidiabetic drug 'Invokana' (chemically known as Canagliflozin) with AChE and SGLT2 to establish a link between the treatment of T2DM and Alzheimer's Disease (AD). Docking study was performed using 'Autodock4.2'. Both hydrophobic and π-π interactions play an important role in the correct positioning of Canagliflozin within SGLT2 and catalytic site (CAS) of AChE to permit docking. Free energy of binding (ΔG) for 'Canagliflozin-SGLT2' interaction and 'Canagliflozin - CAS domain of AChE' interaction were found to be -10.03 kcal/mol and -9.40 kcal/mol, respectively. During 'Canagliflozin-SGLT2' interaction, Canagliflozin was found to interact with the most important amino acid residue Q457 of SGLT2. This residue is known for its interaction with glucose during reabsorption in kidney. However, 'Canagliflozin-CAS domain of AChE' interaction revealed that out of the three amino acids constituting the catalytic triad (S203, H447 and E334), two amino acid residues (S203 and H447) interact with Canagliflozin. Hence, Invokana (Canagliflozin) might act as a potent dual inhibitor of AChE and SGLT2. However, scope still remains in the determination of the three-dimensional structure of SGLT2-Canagliflozin and AChE-Canagliflozin complexes by X-ray crystallography to validate the described data. Since the development of diabetes is associated with AD, the design of new AChE inhibitors based on antidiabetic drug scaffolds would be particularly beneficial. Moreover, the present computational study reveals that Invokana (Canagliflozin) is expected to form the basis of a future dual therapy against diabetes associated neurological disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In silico studies indicate that flozins have the molecular ability to inhibit acetylcholinesterase.”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [58]
In the citing paper
“Canagliflozin was even called a ‘dual inhibitor of SGLT2 and AChE’ as its estimated inhibition constant Ki (i.e., the concentration required to produce half-maximum inhibition) against AChE was 0.12859 µM [58].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [58]
Citations
The citation lists are queued
They are fetched later and appear here then.
Cited by 71
Metadata
- Authors
- Rizvi, S., Shakil, S., Biswas, D., Shakil, S., Shaikh, S., Bagga, P., & Kamal, M.
- Affiliations
- Integral University (IN)
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-05-31
- Volume
- 13
- Issue
- 3
- Pages
- 447-451
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2136780781
- Cited by
- 71
- References
- 0
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 11 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 5 · 2015: 2 · 2014: 1
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS & Neurological Disorders - Drug Targets (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- canagliflozin, acetylcholinesterase, SGLT2, dual enzyme inhibition, Alzheimer's disease, type 2 diabetes, drug repurposing, antidiabetic drugs, catalytic triad, molecular docking, binding free energy
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Computer Simulation, Diabetes Mellitus, Type 2, Glucosides, Humans, Models, Molecular, Thiophenes, Databases, Protein, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study. https://app.cochat.ai/papers/10.2174/18715273113126660160
- The paper
- Rizvi, S., Shakil, S., Biswas, D., Shakil, S., Shaikh, S., Bagga, P., & Kamal, M. (2014). Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/18715273113126660160
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.